IVERIC bio Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 1.09
Market capitalization 2.75B
Operating cash flow -136.97M
ESG Scores unknown

Company description

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -1.68M -241k 7.16M 64k
Total Cashflows From Investing Activities 150k 150k -143.81M 21.3M
Net Borrowings
Total Cash From Financing Activities 6.14M 42.84M 150.58M 272.33M
Change To Operating Activities 3.42M -432k 2.36M 1.61M
Issuance Of Stock 6.14M 42.84M 150.58M 272.33M
Net Income 63.09M -58.86M -84.55M -114.52M
Change In Cash -35.77M -5.5M -59.33M 195.07M
Effect Of Exchange Rate
Total Cash From Operating Activities -41.91M -48.49M -66.1M -98.56M
Depreciation 183k 162k 143k 39k
Change To Account Receivables
Other Cashflows From Financing Activities
Change To Netincome -108.31M 9.12M 8.79M 12.48M
Capital Expenditures -361k -361k -361k -361k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax 62.02M -58.97M -88.24M -114.52M
Net Income 63.09M -58.86M -84.55M -114.52M
Selling General Administrative 23.61M 21.63M 25.95M 29.69M
Gross Profit -34.84M -39.64M -62.78M -85.07M
Ebit -58.45M -61.27M -88.74M -114.76M
Operating Income -58.45M -61.27M -88.74M -114.76M
Interest Expense
Income Tax Expense -1.06M -111k -3.69M
Total Revenue
Cost Of Revenue 34.84M 39.64M 62.78M 85.07M
Total Other Income ExpenseNet 120.47M 2.3M 494k 235k
Net Income From Continuing Ops 63.09M -58.86M -84.55M -114.52M
Net Income Applicable To Common Shares 63.09M -58.86M -84.55M -114.52M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 13.21M 12.98M 25.19M 28.83M
Total Stockholder Equity 123.96M 117.2M 191.56M 360.53M
Other Current Liabilities
Total Assets 137.16M 130.19M 216.75M 389.36M
Common Stock 41k 50k 90k 115k
Other Current Assets
Retained Earnings -421.67M -480.53M -565.07M -679.6M
Treasury Stock 3k -90k
Cash 131.2M 125.7M 66.37M 261.45M
Total Current Liabilities 13.21M 12.98M 25.13M 28.21M
Other Stockholder Equity 3k -90k
Property, Plant, and Equipment 335k 669k 146k 1.87M
Total Current Assets 133.29M 128.62M 216.6M 387.49M
Net Tangible Assets 123.96M 117.2M 191.56M 360.53M
Net Receivables 882k 1.76M
Accounts Payable 5.87M 5.63M 12.79M 12.86M


Insider Transactions

Here are the insider transactions of stock shares related to IVERIC bio Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
DUGEL PRAVIN UConversion of Exercise of derivative security at price 10.03 per share.D2022-11-17President8.47k
SBLENDORIO GLENN PSale at price 23.01 per share.D2022-11-02Chief Executive Officer50k
WESTBY KEITHSale at price 23.92 per share.D2022-11-01Chief Operating Officer72.92k
WESTBY KEITHConversion of Exercise of derivative security at price 1.45 per share.D2022-11-01Chief Operating Officer42.92k
SIMMS CHRISTOPHER PAULSale at price 11.25 per share.D2022-08-03Officer12.27k
SIMMS CHRISTOPHER PAULD2022-08-02Officer33.75k
BLUMENKRANZ MARK SD2022-07-15Director5k
GIBNEY ANTHONY S.Sale at price 9.41 per share.D2022-07-05Officer7.79k
GIBNEY ANTHONY S.D2022-06-30Officer18.75k
ROBERTS CALVIN WPurchase at price 9.62 per share.D2022-06-13Director25k
BLUMENKRANZ MARK SD2022-05-11Director7.5k
GRAVES ADRIENNE LD2022-05-11Director7.5k
HENDERSON JANED2022-05-11Director7.5k
ROBERTS CALVIN WD2022-05-11Director7.5k
BOLTE AXELD2022-05-11Director7.5k
DUGEL PRAVIN UD2022-05-03President4.31k
WESTBY KEITHSale at price 16.63 per share.D2022-04-18Chief Operating Officer10k
WESTBY KEITHSale at price 19.00 - 19.02 per share.D2022-04-05Chief Operating Officer30k
WESTBY KEITHConversion of Exercise of derivative security at price 1.45 per share.D2022-04-05Chief Operating Officer30k
CARROLL DAVID FRANCISSale at price 17.00 - 19.01 per share.D2022-04-05Chief Financial Officer47.77k
CARROLL DAVID FRANCISConversion of Exercise of derivative security at price 1.45 per share.D2022-04-05Chief Financial Officer25k
SBLENDORIO GLENN PSale at price 18.76 per share.D2022-04-04Chief Executive Officer50k
DUGEL PRAVIN UD2022-04-01President50k
SBLENDORIO GLENN PSale at price 17.00 - 17.50 per share.D2022-04-01Chief Executive Officer43.37k
SBLENDORIO GLENN PConversion of Exercise of derivative security at price 2.94 per share.D2022-04-01Chief Executive Officer43.37k
CARROLL DAVID FRANCISSale at price 17.02 per share.D2022-03-25Chief Financial Officer16.77k
CARROLL DAVID FRANCISConversion of Exercise of derivative security at price 1.45 per share.D2022-03-25Chief Financial Officer16.76k
SBLENDORIO GLENN PSale at price 17.06 per share.D2022-03-25Chief Executive Officer18.77k
SBLENDORIO GLENN PConversion of Exercise of derivative security at price 2.94 per share.D2022-03-25Chief Executive Officer18.77k
CARROLL DAVID FRANCISSale at price 17.00 per share.D2022-03-18Chief Financial Officer11.56k
CARROLL DAVID FRANCISConversion of Exercise of derivative security at price 1.45 per share.D2022-03-18Chief Financial Officer8.24k
SBLENDORIO GLENN PSale at price 17.00 per share.D2022-03-18Chief Executive Officer3.48k
SBLENDORIO GLENN PConversion of Exercise of derivative security at price 2.94 per share.D2022-03-18Chief Executive Officer3.48k
WESTBY KEITHSale at price 15.01 - 15.06 per share.D2022-03-17Chief Operating Officer10k
WESTBY KEITHConversion of Exercise of derivative security at price 1.65 per share.D2022-03-01Chief Operating Officer10.17k
WESTBY KEITHSale at price 15.16 per share.D2022-02-15Chief Operating Officer10k
WESTBY KEITHSale at price 15.00 per share.D2022-02-07Chief Operating Officer10k
WESTBY KEITHSale at price 16.39 per share.D2022-01-03Chief Operating Officer12.28k
CARROLL DAVID FRANCISSale at price 16.39 per share.D2022-01-03Chief Financial Officer15.82k
WESTBY KEITHD2021-12-31Chief Operating Officer32.5k
CARROLL DAVID FRANCISD2021-12-31Chief Financial Officer32.5k
SBLENDORIO GLENN PSale at price 17.00 - 17.01 per share.D2021-12-31Chief Executive Officer901
SBLENDORIO GLENN PConversion of Exercise of derivative security at price 2.94 per share.D2021-12-31Chief Executive Officer901
SBLENDORIO GLENN PSale at price 16.50 - 16.96 per share.D2021-12-27Chief Executive Officer58.48k
SBLENDORIO GLENN PConversion of Exercise of derivative security at price 1.45 - 2.94 per share.D2021-12-27Chief Executive Officer58.48k
SBLENDORIO GLENN PStock Gift at price 0.00 per share.D2021-12-23Chief Executive Officer60k
WESTBY KEITHSale at price 15.89 per share.D2021-12-21Chief Operating Officer20k
CARROLL DAVID FRANCISSale at price 15.98 per share.D2021-12-21Chief Financial Officer56.21k
WESTBY KEITHSale at price 15.44 per share.D2021-12-20Chief Operating Officer4.52k
CARROLL DAVID FRANCISSale at price 15.44 per share.D2021-12-20Chief Financial Officer6.71k
SBLENDORIO GLENN PSale at price 15.44 per share.D2021-12-20Chief Executive Officer18.52k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to IVERIC bio Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on IVERIC bio Inc

Here is the result of two systematic investment strategies applied to IVERIC bio Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on IVERIC bio Inc

The following chart shows the equity curve of the two systematic investment strategies applied to IVERIC bio Inc:

IVERIC bio Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 675.5% on the backtest period.

Performance at glance

Performance

675.5 %

Latent gain

11834.53 $

Invested capital

1751.97 $

Annualized return

164.76 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on IVERIC bio Inc

This is the result of two momentum investment strategies applied to IVERIC bio Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on IVERIC bio Inc

The following chart shows all the entries opened by the momentum investment system on IVERIC bio Inc:

IVERIC bio Inc momentum entries
  • The first momentum investment strategy would give 678.26% of return on IVERIC bio Inc. That represents 30589.97$ of latent gain with 4510.05$ of employed capital.
  • The second momentum investment strategy would give 610.36% of return on IVERIC bio Inc. That represents 15312.91$ of latent gain with 2508.83$ of employed capital.
Performance at glance (1Q Momentum)

Performance

678.26 %

Latent gain

30589.97 $

Invested capital

4510.05 $

Annualized return

114.53 %
Performance at glance (2Q Momentum)

Performance

610.36 %

Latent gain

15312.91 $

Invested capital

2508.83 $

Annualized return

168.61 %

Momentum equity curve on IVERIC bio Inc

The following chart shows the equity curve of the two momentum strategies applied to IVERIC bio Inc:

IVERIC bio Inc momentum equity

Note: the dividends potentially given by IVERIC bio Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IVERIC bio Inc

The following chart shows the employed capital evolution of the two momentum strategies on IVERIC bio Inc since the beginning:

IVERIC bio Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on IVERIC bio Inc

Buy the dip entry openings on IVERIC bio Inc

IVERIC bio Inc

The performance achieved by the robo-advisor on IVERIC bio Inc is 240.52%. That represents 1204.53$ of latent gain with 500.81$ of employed capital. The following chart shows IVERIC bio Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of IVERIC bio Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

240.52 %

Latent gain

1204.53 $

Invested capital

500.81 $

Annualized return

114.53 %

Equity curve of the strategy applied to IVERIC bio Inc

The following chart shows the result of the investment strategy applied to IVERIC bio Inc:

IVERIC bio Inc

Note: the dividends potentially given by IVERIC bio Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IVERIC bio Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on IVERIC bio Inc:

IVERIC bio Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on IVERIC bio Inc

In this section, I will compare the three previous investment strategies applied to IVERIC bio Inc.

Equity curve comparison on IVERIC bio Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

IVERIC bio Inc investment strategy comparison

Employed capital comparison on IVERIC bio Inc

IVERIC bio Inc investment comparison

Performance comparison on IVERIC bio Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 675.5% 11834.53$ 1751.97$ 164.76%
Momentum 1 quarter 678.26% 30589.97$ 4510.05$ 175.72%
Momentum 2 quarters 610.36% 15312.91$ 2508.83$ 168.61%
Non-directional 240.52% 1204.53$ 500.81$ 114.53%
Annualized return comparison

Automatic investment

164.76 %

Momentum 1Q

168.61 %

Momentum 2Q

168.61 %

Non-directional

114.53 %

Correlated stocks

Here are the most positively and negatively correlated stocks with IVERIC bio Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • RICH GOLDMAN
  • SOLOCAL GROUP

  • Note: The algorithm computes the probability of correlation between IVERIC bio Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of IVERIC bio Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name IVERIC bio Inc
    Country United States
    City Parsippany
    Address 8 Sylvan Way
    Phone 609 474 6755
    Website ivericbio.com
    FullTime employees 148
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker ISEE
    Market www.nasdaq.com

    IVERIC bio Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown